Literature DB >> 10216095

Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.

M Kockx1, P P Gervois, P Poulain, B Derudas, J M Peters, F J Gonzalez, H M Princen, T Kooistra, B Staels.   

Abstract

Plasma fibrinogen levels have been identified as an important risk factor for cardiovascular diseases. Among the few compounds known to lower circulating fibrinogen levels in humans are certain fibrates. We have studied the regulation of fibrinogen gene expression by fibrates in rodents. Treatment of adult male rats with fenofibrate (0.5% [wt/wt] in the diet) for 7 days decreased hepatic Aalpha-, Bbeta-, and gamma-chain mRNA levels to 52% +/- 7%, 46% +/- 8%, and 81% +/- 19% of control values, respectively. In parallel, plasma fibrinogen concentrations were decreased to 63% +/- 7% of controls. The suppression of fibrinogen expression was dose-dependent and was already evident after 1 day at the highest dose of fenofibrate tested (0.5% [wt/wt]). Nuclear run-on experiments showed that the decrease in fibrinogen expression after fenofibrate occurred at the transcriptional level, as exemplified for the gene for the Aalpha-chain. Other fibrates tested showed similar effects on fibrinogen expression and transcription. The effect of fibrates is specific for peroxisome proliferator-activated receptor-alpha (PPARalpha) because a high-affinity ligand for PPARgamma, the thiazolidinedione BRL 49653, lowered triglyceride levels, but was unable to suppress fibrinogen expression. Direct evidence for the involvement of PPARalpha in the suppression of fibrinogen by fibrates was obtained using PPARalpha-null (-/-) mice. Compared with (+/+) mice, plasma fibrinogen levels in (-/-) mice were significantly higher (3.20 +/- 0.48 v 2.67 +/- 0.42 g/L). Also, hepatic fibrinogen Aalpha-chain mRNA levels were 25% +/- 11% higher in the (-/-) mice. On treatment with 0.2% (wt/wt) fenofibrate, a significant decrease in plasma fibrinogen to 77% +/- 10% of control levels and in hepatic fibrinogen Aalpha-chain mRNA levels to 65% +/- 12% of control levels was seen in (+/+) mice, but not in (-/-) mice. These studies show that PPARalpha regulates basal levels of plasma fibrinogen and establish that fibrate-suppressed expression of fibrinogen in rodents is mediated through PPARalpha.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216095

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule.

Authors:  Hwi-Yeol Yun; Eun Joo Lee; Soo Youn Chung; Sun-Ok Choi; Hyung Kee Kim; Jun-Tack Kwon; Wonku Kang; Kwang-Il Kwon
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  PPARs and molecular mechanisms of transrepression.

Authors:  Mercedes Ricote; Christopher K Glass
Journal:  Biochim Biophys Acta       Date:  2007-03-12

Review 3.  Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance.

Authors:  Geoffrey A Preidis; Kang Ho Kim; David D Moore
Journal:  J Clin Invest       Date:  2017-03-13       Impact factor: 14.808

Review 4.  Fibrinogen and coronary risk.

Authors:  W Koenig
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

Review 5.  The role of fibric acids in atherosclerosis.

Authors:  J C Fruchart; B Staels; P Duriez
Journal:  Curr Atheroscler Rep       Date:  2001-01       Impact factor: 5.113

6.  PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a.

Authors:  Florence Gizard; Carole Amant; Olivier Barbier; Stefano Bellosta; Romain Robillard; Frédéric Percevault; Henry Sevestre; Paul Krimpenfort; Alberto Corsini; Jacques Rochette; Corine Glineur; Jean-Charles Fruchart; Gérard Torpier; Bart Staels
Journal:  J Clin Invest       Date:  2005-11       Impact factor: 14.808

7.  Peroxisome proliferator-activated receptor alpha target genes.

Authors:  Maryam Rakhshandehroo; Bianca Knoch; Michael Müller; Sander Kersten
Journal:  PPAR Res       Date:  2010-09-26       Impact factor: 4.964

Review 8.  Role of fibrinogen in cerebrovascular dysfunction after traumatic brain injury.

Authors:  Nino Muradashvili; David Lominadze
Journal:  Brain Inj       Date:  2013-09-24       Impact factor: 2.311

9.  Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions.

Authors:  Hetal D Shah; Keyur H Parikh; Milan C Chag; Urmil G Shah; Hemang A Baxi; Anish H Chandarana; Ajay M Naik; Joyal N Shah; Sangeeta Iyer; Kanan J Shah; Ramesh K Goyal
Journal:  Exp Clin Cardiol       Date:  2007

Review 10.  Fibrinogen and Neuroinflammation During Traumatic Brain Injury.

Authors:  Nurul Sulimai; David Lominadze
Journal:  Mol Neurobiol       Date:  2020-08-10       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.